Mirati Therapeutics Inc (DELISTED) (MRTX:DL)
58.70
0.00 (0.00%)
USD |
NASDAQ |
Jan 23, 16:00
Mirati Therapeutics Research and Development Expense (TTM): 506.87M for Sept. 30, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | 506.87M |
| June 30, 2023 | 523.18M |
| March 31, 2023 | 527.33M |
| December 31, 2022 | 531.63M |
| September 30, 2022 | 544.23M |
| June 30, 2022 | 529.26M |
| March 31, 2022 | 535.50M |
| December 31, 2021 | 508.59M |
| September 30, 2021 | 437.46M |
| June 30, 2021 | 401.20M |
| March 31, 2021 | 331.71M |
| December 31, 2020 | 299.35M |
| September 30, 2020 | 279.58M |
| June 30, 2020 | 247.09M |
| March 31, 2020 | 220.34M |
| December 31, 2019 | 182.87M |
| September 30, 2019 | 146.68M |
| June 30, 2019 | 122.95M |
| March 31, 2019 | 108.45M |
| December 31, 2018 | 93.87M |
| September 30, 2018 | 82.36M |
| June 30, 2018 | 72.21M |
| March 31, 2018 | 63.35M |
| December 31, 2017 | 58.08M |
| September 30, 2017 | 58.79M |
| Date | Value |
|---|---|
| June 30, 2017 | 61.42M |
| March 31, 2017 | 64.90M |
| December 31, 2016 | 68.49M |
| September 30, 2016 | 67.45M |
| June 30, 2016 | 65.90M |
| March 31, 2016 | 58.74M |
| December 31, 2015 | 48.96M |
| September 30, 2015 | 41.12M |
| June 30, 2015 | 33.44M |
| March 31, 2015 | 29.32M |
| December 31, 2014 | 26.07M |
| September 30, 2014 | 23.32M |
| June 30, 2014 | 21.92M |
| March 31, 2014 | 19.28M |
| December 31, 2013 | 19.80M |
| September 30, 2013 | 20.45M |
| June 30, 2013 | 19.21M |
| March 31, 2013 | 18.35M |
| December 31, 2012 | 15.08M |
| September 30, 2012 | 13.26M |
| June 30, 2012 | 11.02M |
| March 31, 2012 | 9.221M |
| December 31, 2011 | 8.800M |
| September 30, 2011 | 7.118M |
| June 30, 2011 | 7.637M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
122.95M
Minimum
Jun 2019
544.23M
Maximum
Sep 2022
381.99M
Average
419.33M
Median
Research and Development Expense (TTM) Benchmarks
| Bristol-Myers Squibb Co | 9.673B |
| Karuna Therapeutics Inc (DELISTED) | 364.10M |
| Puma Biotechnology Inc | 51.26M |
| NovaBay Pharmaceuticals Inc | 0.061M |
| Palatin Technologies Inc | 25.13M |